Cargando…

3′-Deoxy-3′-[(18)F]-Fluorothymidine PET Imaging Reflects PI3K-mTOR-Mediated Pro-Survival Response to Targeted Therapy in Colorectal Cancer

Biomarkers that predict response to targeted therapy in oncology are an essential component of personalized medicine. In preclinical treatment response studies that featured models of wild-type KRAS or mutant BRAF colorectal cancer treated with either cetuximab or vemurafenib, respectively, we illus...

Descripción completa

Detalles Bibliográficos
Autores principales:	McKinley, Eliot T., Zhao, Ping, Coffey, Robert J., Washington, M. Kay, Manning, H. Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172755/ https://www.ncbi.nlm.nih.gov/pubmed/25247710 http://dx.doi.org/10.1371/journal.pone.0108193

Ejemplares similares

Preclinical Applications of 3'-Deoxy-3'-[(18)F]Fluorothymidine in Oncology - A Systematic Review
por: Schelhaas, Sonja, et al.
Publicado: (2017)

Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
por: Kairemo, Kalevi, et al.
Publicado: (2020)

Mismatched intratumoral distribution of [(18)F] fluorodeoxyglucose and 3′-deoxy-3′-[(18)F] fluorothymidine in patients with lung cancer
por: Wang, Xiangcheng, et al.
Publicado: (2017)

Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3′-deoxy-3′-[18F] fluorothymidine in patients with lung cancer
por: Wang, Xiangcheng, et al.
Publicado: (2018)

Relative skeletal distribution of proliferating marrow in the adult dog determined using 3′‐deoxy‐3′‐[(18)F]fluorothymidine
por: Rowe, Joshua A., et al.
Publicado: (2018)

Preliminary (19)F-MRS Study of Tumor Cell Proliferation with 3′-deoxy-3′-fluorothymidine and Its Metabolite (FLT-MP)
por: Ko, In Ok, et al.
Publicado: (2017)

Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study
por: Kairemo, Kalevi, et al.
Publicado: (2020)

Limits of [(18)F]-FLT PET as a Biomarker of Proliferation in Oncology
por: McKinley, Eliot T., et al.
Publicado: (2013)

Comparison of Positron Emission Tomography Using 2-[(18)F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[(18)F]-fluorothymidine in Lung Cancer Imaging
por: Wang, Fu-Li, et al.
Publicado: (2016)

Validity of Simplified 3′-Deoxy-3′-[(18)F]Fluorothymidine Uptake Measures for Monitoring Response to Chemotherapy in Locally Advanced Breast Cancer
por: Lubberink, Mark, et al.
Publicado: (2012)

Predictive value of 3′-deoxy-3′-(18)F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer
por: Sato, Masayuki, et al.
Publicado: (2021)

Phosphorylation Status of Thymidine Kinase 1 Following Antiproliferative Drug Treatment Mediates 3′-Deoxy-3′-[(18)F]-Fluorothymidine Cellular Retention
por: Sala, Roberta, et al.
Publicado: (2014)

Clinical value of 3'-deoxy-3'-[(18)F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer
por: Alwadani, Bandar, et al.
Publicado: (2021)

The Influence of Interpreters’ Professional Background and Experience on the Interpretation of Multimodality Imaging of Pulmonary Lesions Using( 18)F-3′-Deoxy-Fluorothymidine and (18)F-Fluorodeoxyglucose PET/CT
por: Xu, Bai-xuan, et al.
Publicado: (2013)

Synthesis and evaluation of 3′-[(18)F]fluorothymidine-5′-squaryl as a bioisostere of 3′-[(18)F]fluorothymidine-5′-monophosphate
por: Brickute, D., et al.
Publicado: (2021)

Comparison of 4′-[methyl-(11)C]thiothymidine ((11)C-4DST) and 3′-deoxy-3′-[(18)F]fluorothymidine ((18)F-FLT) PET/CT in human brain glioma imaging
por: Toyota, Yasunori, et al.
Publicado: (2015)

Exploratory Analysis of (18)F-3’-deoxy-3’-fluorothymidine ((18)F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer
por: Fantini, Lorenzo, et al.
Publicado: (2021)

mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers
por: Deming, Dustin A., et al.
Publicado: (2013)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

(18)F-fluorothymidine PET imaging in gliomas: an update
por: Nikaki, Alexandra, et al.
Publicado: (2017)

Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses
por: Turcotte, Eric, et al.
Publicado: (2007)

An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3′-deoxy-3′[(18)F]-Fluorothymidine Positron Emission Tomography (18)F-FLT PET/CT in Prostate Adenocarcinoma
por: Kairemo, Kalevi, et al.
Publicado: (2017)

NLRC3 is an inhibitory sensor of PI3K–mTOR pathways in cancer
por: Karki, Rajendra, et al.
Publicado: (2016)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells
por: Gamper, Christopher J., et al.
Publicado: (2012)

Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[(18)F]fluorothymidine Positron Emission Tomography
por: Frings, Virginie, et al.
Publicado: (2013)

The Positron Emission Tomography Tracer 3’-Deoxy-3’-[(18)F]Fluorothymidine ([(18)F]FLT) Is Not Suitable to Detect Tissue Proliferation Induced by Systemic Yersinia enterocolitica Infection in Mice
por: Wiehr, Stefan, et al.
Publicado: (2016)

Role of 3'-Deoxy-3'-[(18)F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase
por: Szyszko, Teresa A., et al.
Publicado: (2022)

Genomewide Analysis of Inherited Variation Associated with Phosphorylation of PI3K/AKT/mTOR Signaling Proteins
por: Hutz, Janna E., et al.
Publicado: (2011)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Voxel-Based Analysis of the Relation of 3′-Deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) PET and Diffusion-Weighted (DW) MR Signals in Subcutaneous Tumor Xenografts Does Not Reveal a Direct Spatial Relation of These Two Parameters
por: Schelhaas, Sonja, et al.
Publicado: (2021)

3’-Deoxy-3’-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study
por: Lewis, Shirley, et al.
Publicado: (2022)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
por: Yang, Shujie, et al.
Publicado: (2011)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ltc4r98q5brucjqtssu6bg04l0